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Representative data on the extent of endemicity, burden, and risk of human toxoplasmosis are scarce. 
We assessed the prevalence and determinants of seropositivity of Toxoplasma gondii among adult 
participants of a nationwide representative cross-sectional survey in Germany. Sera collected from a 
representative cohort of adults (age 18–79; n = 6,663) in Germany were tested for anti-T. gondii IgG 
antibodies. Interview-derived data were used to evaluate associated factors. Multivariable logistic 
regression was applied using sampling weights and accounting for survey design cluster effects. 
Seroprevalence increased from 20% (95%-CI:17–23%) in the 18–29 age group to 77% (95%-CI:73–81%) 
in the 70–79 age group. Male gender, keeping cats and BMI ≥30 were independent risk factors for 
seropositivity, while being vegetarian and high socio-economic status were negatively associated. 
Based on these data, we estimate 1.1% of adults and 1.3% of women aged 18–49 to seroconvert each 
year. This implies 6,393 seroconversions annually during pregnancies. We conclude that T. gondii 
infection in Germany is highly prevalent and that eating habits (consuming raw meat) appear to be of 
high epidemiological relevance. High numbers of seroconversions during pregnancies pose substantial 
risks for unborn children. Efforts to raise awareness of toxoplasmosis in public health programs 
targeting to T. gondii transmission control are therefore strongly advocated.
Infection with the protozoan parasite Toxoplasma gondii, the causative agent of toxoplasmosis, is a very common 
human disease worldwide1,2. T. gondii persists lifelong in the affected host organism. In cats and other feline 
obligate hosts, parasites reproduce sexually and shed up to hundreds of millions of oocysts. They resist moderate 
environmental conditions, and contaminate water and soil where they undergo sporulation. The resulting form is 
responsible for infection via ingestion of either contaminated food, water or dust3,4. Additionally, parasites can be 
found as tissue cysts in all warm-blooded animals including livestock. Eating raw or undercooked infected meat 
is thus a second epidemiologically-relevant mode of transmission5. Transfer of parasites, e.g. through infected 
transplants or vertically in utero, is an additional route of transmission1,2.
In humans, most infections remain asymptomatic or manifest with mild flu-like symptoms; however, severe 
forms can occur6,7. These include congenital toxoplasmosis that can develop when a woman becomes primary 
infected with T. gondii during pregnancy2,8. Clinical surveys demonstrate that up to 20% of such maternal infec-
tions result in transplacental transmission, and that in 27% of the infected neonates specific symptoms develop9,10. 
Depending on the gestational age of the fetus at infection, predominantly retinochoroiditis, calcifications, hydro-
cephalus, psychomotoric and neurological disabilities, and fetal death can develop6,7.
After diagnosis of maternal infection, fast initiation of therapy can efficiently reduce the risk of transpla-
cental transmission and thus lower the disease burden of the newborn11–14. However, timely diagnosis can only 
be achieved through systematic screening of pregnant women. This is currently recommended in France and 
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Austria, but in the absence of strong evidence of its benefit, not in the UK and in Germany15.The reasons are 
diverse, but it is argued that the cost of the initial as well as follow up tests and the errors that arise are not out-
weighed by the small number of infections that can be prevented16 (see also Discussion).
T. gondii infection is also an important cause of visual impairment. Infection at ocular sites (retina and the 
choroid) causes lesions leading to retinal scarring6,7. In a population-based study in Britain, the lifetime risk of 
symptomatic T. gondii-associated ocular disease was determined to be 18 in 100,000 individuals17. In Germany, 
4.2% of uveitis cases are thought to be due to T. gondii infections6.
Acute and reactivating infections in immunocompromised persons (e.g. AIDS patients or transplant recipients) 
can affect the central nervous system. An incidence of 3% of cerebral toxoplasmosis, associated with poor prog-
nosis, was found among allogeneic hematopoietic stem cell transplant recipients18,19. Collectively, different mani-
festations of toxoplasmosis lead to a significant amount of years of life lost and many life years lived with sequelae, 
which constitute an exceptionally high disease burden of public health concern20–23.
Apart from the well-proven clinical entities, persistent infections with T. gondii are suspected to be connected 
to mood disorders24. In the United States National Health and Nutrition Survey, prevalence of serum anti-T. gondii 
IgG was not elevated in unipolar mood disorders, like depression, but was higher in a subset of respondents with 
a history of bipolar disorder25. However, the link between T. gondii infection and neurological changes in humans 
awaits experimental verification and thus remains highly controversial.
Congenital toxoplasmosis is mandatorily notifiable to the Robert Koch Institute, which is responsible for the 
implementation of data collection and processing of anonymized case data inside the infectious disease noti-
fication system of Germany. It is suspected that these data are subject to a high level of underreporting and 
under-ascertainment of disease. Thus, information on disease incidence is missing. Previous serosurveys for 
T. gondii are limited regarding representativeness and sample size. Available studies are based on convenience 
sampling (mainly pregnant females) and lack a random selection of participants.
Our objectives were thus to assess the seroprevalence of T. gondii IgG antibodies from the population-based 
German representative health interview and examination survey of adults (DEGS1)26, to identify and quantify 
the contribution of factors potentially associated with T. gondii seropositivity and to estimate the annual number 
of infections during pregnancy in Germany.
Results
Seroprevalence and associated factors. Altogether 6,663 participants with available blood samples were 
included in this study; 99 (1.5%) thereof had equivocal anti-T. gondii IgG titers of 4–7 and were thus excluded from 
the analysis. Out of 6,564 individuals, 3,602 (55%) were seropositive (Table 1). Seroprevalence increased from 20% 
(95%-confidence interval (95%-CI):17.1–23.1%) in the age group 18–29 to 77% (95%-CI:72.7–80.5%) in the 70–79 
age group. Seroprevalence in participants older than 79 years (n = 116), not included in further analyses, was 84%. 
The observed seroprevalence increased at a rate of 1.09% with each year of age (Fig. 1). A significant interaction 
was noted between age and sex (p-value = 0.023), since higher seroprevalences were observed among younger 
males and older females. Male gender, although not associated in univariable analysis, was a significant risk fac-
tor in multivariable analysis (odds ratio (OR): 1.8; 95%-CI1.1–2.9). Age-related increase of seroprevalence was 
stronger amongst residents of East Germany when compared to the West (p-value of interaction term: < 0.001) 
(Fig. 2). Prevalence in East Germany is more than 20% higher than in West Germany in the 40–69 age group.
Factors positively associated with seropositivity included cat contact. 15.8% of the participants indicated keep-
ing a cat in the household, which proved to be a risk factor for seropositivity by multivariable analysis (OR: 1.3; 
95%-CI:1.1–1.5), whereas holding a dog or other companion animal had no impact. Being overweight (25 ≤ BMI 
<30) or obese (BMI ≥30) was also positively associated with seropositivity (OR of 1.2; 95%-CI:1.0–1.5; and 
OR: 1.3; 95%-CI:1.0–1.6, respectively). People living in rural areas had an increased risk of infection (OR: 1.41; 
95%-CI:1.1–1.8) compared to inhabitants of bigger cities. Factors negatively associated with T. gondii infection were 
being vegetarian (OR: 0.6; 95%-CI:0.4–1.0) and having a high socio-economic status (OR: 0.7; 95%-CI:0.6–0.9). 
No association could be found with diabetes.
Incidence estimates of seroconversions. Using a regression model we estimated an annual incidence 
of 1,099 (95% CI:1,016–1,181) seroconversions per 100,000 adult inhabitants of Germany (Table 2). In women 
aged 18–49 (considered here as main age group potentially bearing children) this corresponds to 1,325 (95% CI: 
1,007–1,642) seroconversions. Taking the age-dependent distribution of births among women (data from 2011) 
and an age-related increase in seroprevalence into account, it can be assumed that 74.1% of births were delivered 
by mothers susceptible to primary infection (“pregnancies at risk”). The susceptibility decreased from 90.8% in 
the age group 15–19 years to 52.6% in those 45–49 years old. The incidence of 1,325 in 100,000 women implied 
6,393 predicted infections during the annual 662, 485 pregnancies in Germany (Table 3). These are 1.0% of all 
pregnant women and 1.3% of seronegative pregnant women (pregnancies at risk).
Estimates of incidence of congenital toxoplasmosis. In a recent meta-analysis among patient 
cohorts, the rate of mother-to-child transmission among seroconverting pregnant women was reported to be 
20% (95%-CI:15–26%)9. Extrapolated to the numbers derived here this would result in 1,279 (95% CI:959–1,662) 
annual cases of fetal infections in Germany. Based on estimates that 27% of infected neonates manifest with 
T. gondii-specific symptoms10, this would result in 345 neonates with clinical symptoms (congenital toxoplasmo-
sis) annually in Germany.
Depression. Participants in the survey who recalled an episode of depression during their lifetime had no 
association with seropositivity in univariable analysis (OR: 0.94; 95%-CI:0.78–1.13) (Table 4). This is confirmed 
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Characteristic (total no.)a n (pos)a Prevalence in % (95% CI)
Univariable analysis Multivariable analysis
Odds ratio (95% CI) p-Value Odds ratio (95% CI) p-Value
Sex
 Women (n = 3,443) 1,864 48.85 (46.56–51.14) ref ref ref ref
 Men (n = 3,121) 1,738 49.31 (46.35–52.27) 1.02 (0.90–1.15) 0.767 1.76 (1.08–2.91) 0.023
 Interaction term sex*age – – – – 0.99 (0.98–1.00) 0.024
Age
 Yearly – – 1.05 (1.05–1.06) < 0.001 1.06 (1.05–1.06) < 0.001
Age group (years)
 18–29 (n = 994) 214 19.95 (17.10–23.13) ref ref – –
 30–39 (n = 790) 301 35.46 (31.01–40.17) 2.21 (1.70–2.85) < 0.001 – –
 40–49 (n = 1,212) 628 48.10 (44.57–51.64) 3.72 (3.00–4.60) < 0.001 – –
 50–59 (n = 1,298) 796 57.97 (54.25–61.61) 5.54 (4.37–7.01) < 0.001 – –
 60–69 (n = 1,267) 903 69.48 (65.13–73.50) 9.13 (7.01–11.89) < 0.001 – –
 70–79 (n = 1,003) 760 76.82 (72.74–80.45) 13.30 (10.20–17.34) < 0.001 – –
Residence (East-West)b
 West (n = 4,484) 2,067 44.02 (42.10–45.96) ref ref ref ref
 East (n = 2,080) 1,535 68.17 (64.13–71.95) 2.72 (2.24–3.30) < 0.001 0.98 (0.56–1.71) 0.936
 Interact term East*age – – – – 1.03 (1.02–1.04) < 0.001
Residence (north-south)c
 North (n = 1,683) 1,029 53.90 49.94–57.81) 1.46 (1.20–1.79) < 0.001 1.17 (0.93–1.46) 0.177
 Middle (n = 2,879) 1,650 50.04 (46.12–53.96) 1.26 (1.02–1.53) 0.026 0.98 (0.80–1.20) 0.859
 South (n = 2,002) 923 44.38 (41.23–47.58) ref ref ref ref
Population of municipality
 < 5,000 (n = 1,171) 725 56.21 (49.89–62.35) 1.67 (1.27–2.19) < 0.001 1.41 (1.11–1.79) 0.005
 5,000–< 20,000 (n = 1,598) 904 52.11 (47.50–56.69) 1.41 (1.14–1.76) 0.002 1.18 (0.97–1.44) 0.100
 20,000–< 100,000 (n = 1,941) 975 43.50 (40.35–46.71) ref ref ref ref
 > 100,000 (n = 1,854) 998 48.72 (44.68–52.79) 1.23 (1.01–1.51) 0.043 1.17 (0.96–1.43) 0.118
Pet in householdd
 No pet (n = 4,360) 2,400 49.00 (46.64–51.36) ref ref – –
 Any pet (n = 2,045) 1,099 48.46 (45.38–51.55) 0.98 (0.87–1.10) 0.718 – –
Dogd
 No (n = 5,588) 3,070 49.19 (46.93–51.46) ref ref – –
 Yes (n = 806) 424 46.66 (41.94–51.45) 0.90 (0.75–1.09) 0.288 – –
Catd
 No (n = 5,383) 2,936 48.37 (45.99–50.76) ref ref ref ref
 Yes (n = 1,011) 558 51.46 (47.70–55.21) 1.13 (0.97–1.32) 0.127 1.27 (1.06–1.51) 0.009
Other animalsd
 No (n = 5,679) 3,126 49.29 (47.04–51.54) ref ref – –
 Yes (n = 715) 368 45.73 (40.62–50.93) 0.87 (0.71–1.06) 0.168 – –
Eating vegetariand
 No (n = 6,148) 3,413 49.74 (47.54–51.93) ref ref ref ref
 Yes (n = 248) 94 35.77 (28.21–44.11) 0.56 (0.40–0.80 0.002 0.62 (0.42–0.99) 0.048
Body mass index (BMI)
 Underweight (BMI < 18.5) (n = 86) 22 23.95 (14.44–37.02) 0.50 (0.27–0.94) 0.031 0.66 (0.34–1.28) 0.212
 Normal weight (18.5 ≤ BMI < 25) (n = 2,430) 1,063 38.44 (35.83–41.12) ref ref ref ref
 Overweight (25 ≤ BMI < 30) (n = 2,457) 1,470 54.94 (52.08–57.76) 1.95 (1.70–2.24) < 0.001 1.23 (1.03–1.47) 0.024
 Obesity (BMI ≥ 30) (n = 1,552) 1,023 58.99 (55.53–62.39) 2.35 (2.15–2.55) < 0.001 1.28 (1.01–1.55) 0.048
Diabetes (12 month prevalence)
 No (n = 6,072) 3,253 47.92 (45.76–50.10) ref ref ref ref
 Yes (n = 432) 313 67.12 (60.87–72.82) 2.22 (1.70–2.90) < 0.001 0.82 (0.61–1.10) 0.181
Socio-economic statuse
 Low (n = 1,034) 617 54.93 (50.97–58.83) 1.23 (1.03–1.47) 0.024 1.20 (0.95–1.52) 0.132
 Middle (n = 3,933) 2,217 49.77 (47.13–52.43) ref ref ref ref
 High (n = 1,553) 745 41.42 (38.09–44.83) 0.71 (0.61–0.83) < 0.001 0.72 (0.60–0.85) < 0.001
Total (n = 6,564) 3,602 49.08 (46.92–51.23) – – – –
Table 1. Stratified seroprevalence of IgG antibodies against T. gondii detected by ELFA in adults aged 18 to 79 
years and results of weighted logistic regression analysis of potential risk factors for seropositivity, 2008–2011. 
aunweighted. bEastern states: Berlin, Brandenburg, Mecklenburg-West Pomerania, Saxony, Saxony-Anhalt, Thuringia. 
Western states: Baden-Württemberg, Bavaria, Bremen, Hamburg, Hesse, Lower Saxony, Northrhine-Westfalia, 
Rhineland-Palatinate, Saarland, Schleswig-Holstein. cNorthern states: Schleswig-Holstein, Hamburg, Lower Saxony, 
Bremen, Berlin, Brandenburg, Mecklenburg-West Pomerania. Middle states: Nordrhine-Westfalia, Hesse, Saxony, 
Saxony-Anhalt, Thuringia. Southern states: Rhineland-Palatinate, Baden-Württemberg, Bavaria, Saarland. dat day of 
interview. eSocio-economic status is measured using a score composed of income, education and professional status.
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by multivariable analysis adjusted for age and gender as well as for associated factors (OR: 0.84; 95%-CI:0.55–
1.29) from analysis in Table 1.
Discussion
This first nationwide representative seroprevalence study for T. gondii antibodies in Germany finds a high sero-
prevalence compared to other countries. Comparing our findings to previous data from Germany is hampered 
by the older studies’ lack of representativeness, but higher prevalences were found in a serosurvey among blood 
donors between 1994 and 1996 in North-East Germany (59%; n = 4,854; age 20–40)27, as well as in a study among 
pregnant women from South-West Germany (39%; n = 5,670; age 15–47)28. Thus our findings suggest a decrease 
in T. gondii infections in Germany over the last two decades. Similarly, in France, where comprehensive sero-
surveys reported a higher overall seropositivity in women of childbearing age (36.7%; n = 15,130; age 15–49), 
it decreased from 54.2% in 1995 to 43.8% in 2003 and to 36.7% in 201029. In The Netherlands in 2006–2007, 
seroprevalence was significantly lower than in our study (26%; n = 5,541; age 0–79), decreasing from 41% in 
1995/199630. In the USA, seroprevalence declined from 14.1%; in 1988–1994 to 9.0% (n = 10,477; age 12–49) 
in 1999–200431. These differences show that improvements for T. gondii infection prevention in Germany are 
necessary and also possible.
The case numbers from the German notification system are restricted to congenital toxoplasmosis and 
range between 23 cases in 2008 and 6 cases in 2014, without obvious time trends or regional clustering32. This is 
only a small fraction of cases we calculated in this study. Reasons for this discrepancy could be a high degree of 
under-ascertainment and under-reporting, as not all cases of congenital toxoplasmosis are laboratory confirmed, 
and laboratories do not have the clinical or demographic information to carry out the notification. As a result, 
current notification rates do not reflect the full picture of disease burden in Germany. Our extrapolations used 
Figure 1. Estimated T. gondii seroprevalence, by age (18–79 years) and gender, in Germany, 2008–2011. 
Figure 2. Estimated T. gondii seroprevalence, by geographical origin (East-West) and gender, in Germany, 
2008–2011. Berlin is considered as East.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:22551 | DOI: 10.1038/srep22551
manifestation rates from Li et al.9 and Dunn et al.10 for the calculation of incidence of congenital toxoplasmo-
sis,which is independent of the influence of disease surveillance processes and therefore might provide a more 
accurate picture.
Calculations of the incidence of ocular and cerebral toxoplasmosis based on seroconversion rates are difficult, 
since information from surveys on manifestation rates is scarce, and the few sources available are outdated. Jones 
and Holland33 estimated, based on North American surveys in the 1970s, that 2% of T. gondii-infected individuals 
develop ocular toxoplasmosis. Extrapolated to incidence of seroconversion in Germany, this results in 22 patients 
of clinical ocular toxoplasmosis per 100,000 inhabitants annually. Due to an increase of immunosuppression in 
the aging population it can be assumed that incidence of cerebral toxoplasmosis is also increasing, although data 
on the population level are missing.
We found no evidence for a role for T. gondii in depression. This supports previous evidence from the 
population-based United States National Health and Nutrition Survey (NHANES III)25. Altogether, evidence on 
manifestation rates of all health outcomes of T. gondii infections is scarce and therefore studies have to be initiated 
to eliminate these limitations and to fully understand the disease burden of toxoplasmosis.
Seropositivity strongly increases in all age groups, indicating a strong force of infection also in the elderly. 
Frequent seroconversion in this group is particularly problematic since immunosuppression becomes more 
Age group





 18–79 years 1,189 1,077–1,301
 18–49 years 1,325 1,007–1,642
 50–79 years 944 620–1,268
Men
 18–79 years 1,007 897–1,117
 18–49 years 1,436 1,186–1,686
 50–79 years 794 454–1,134
Total 1,099 1,016–1,181
Table 2.  Annual incidence of seroconversions of IgG antibodies against T. gondii stratified by sex and age 
groups.


















Annual expected number of 
seroconversions among pregnancies 
(% of pregnancies at risk)
15–19 1,985,672 26,310 16,459 0.83 90.8 159 (1.1)
20–24 2,421,962 32,091 88,777 3.67 84.5 857 (1.1)
25–29 2,447,109 32,424 191,010 7.81 78.1 1,843 (1.2)
30–34 2,437,824 32,301 222,218 9.12 71.7 2,144 (1.3)
35–39 2,359,922 31,269 115,634 4.90 65.4 1,116 (1.5)
40–44 3,116,101 41,288 27,131 0.87 59.0 262 (1.6)
45–49 3,490,840 46,254 1,256 0.04 52.6 12 (1.8)
Total 18,259,430 241,937 662,485 – 74.1 6,393 (1.3)
Table 3.  Seroprevalence of T. gondii infection by age group in women of childbearing age. aEstimates for the 
15–17 year-old were derived from the study data assuming constant increase as in the age group 18 to 25 years. 
bGerman Federal statistical office, 2011. cat an incidence of 1,325 in 100,000 inhabitants. dinverse of prevalence, 
estimates from the regression model.
Lifetime depression 
(total no.)a n (pos)a Prevalence (95% CI)
Univariable analysis Multivariable analysisb Multivariable analysisc
Odds ratio  
(95% CI) p-Value








No (n = 5,747) 3,161 49.12 (46.90–51.34) ref ref ref ref ref ref
Yes (n = 768) 409 47.56 (43.05–52.11) 0.94 (0.78–1.13) 0.497 1.05 (0.84–1.19) 0.365 0.84 (0.55–1.29) 0.420
Table 4.  Stratified seroprevalence of IgG antibodies against T. gondii detected by ELFA in adults aged 18 to 
79 years, and results of weighted logistic regression analysis of seropositivity on depression as an outcome, 
2008–2011. aunweighted, lifetime incidence of depression (self-reported) was assessed by asking the closed 
question “Have you ever been diagnosed with depression by a physician or a psychotherapist”? badjusted for age, 
sex and interaction between both. cadjusted for variables in multivariable model of Table 1.
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prominent with age. The observed increase is particularly strong in East Germany, arguing that the risk pattern 
changed after unification of Germany in 1990. Alternatively, this could be explained by a birth cohort effect of a 
previous time frame, when a higher risk of seroconversion resulted in higher seroprevalence today in older age 
groups. Although not associated in univariable analysis, men have a 1.76-times higher chance of being seropos-
itive in multivariable analysis. This can be explained by effect modification of the factors higher socio-economic 
status, cat holding and male gender included in the final model. Since male Germans eat about twice as much 
meat and meat products as females34, the higher seroprevalence we observe in men can be reconciled with these 
eating habits. In our study, seroprevalences for T. gondii vary between regions in Germany. The consumption of 
freshly prepared raw minced meat (beef and pork), known in Germany as “Hackepeter” or “Mett”, is more wide-
spread in East compared to West Germany35,36. This may explain the higher seroprevalence in East Germany and 
additionally confirms that raw meat poses a substantial risk for infection with T. gondii4,37.
Furthermore, our results show that overweight and obese study participants have an increased chance of 
becoming seropositive, consistent with recent data from a smaller study in Germany38. There is good evidence 
that higher meat consumption is connected to an increase in body weight39,40,which in turn leads to a higher 
chance to ingest contaminated meat. Eating vegetarian, on the other hand, is negatively associated with sero-
positivity, arguing that consumption of oocyst-contaminated vegetables is not a major driver of seroconversion. 
Altogether, these data are consistent with the majority of infections being food-borne4,37,41.
Some previous epidemiological studies did not observe an elevated risk for cat owners37,42, while representative 
serosurveys in The Netherlands have reported such an association30,43. A case-control study in the USA reported 
a higher risk for cat owners with 3 or more cats44. Cats are biologically essential in the life cycle of T. gondii,  
but cat exposure seems to be a less important factor compared to exposure to contaminated food, in particular 
meat. Nevertheless, prevention of infection through contact with cats is possible since they shed oocysts only for 
1–3 periods during lifetime, and sporulation can be avoided by daily removal of cat litter45.
The strengths of our study include a large sample size with a sampling process leading to a representative study 
population, with an appropriate adjustment for demographic variables. As the DEGS1 study recruited only the 
adult population, we have no data on infants and children. This deficiency should be addressed in the future. The 
analyses in our study are based on seroprevalence data, but seroconversion is not equivalent to clinical manifes-
tation of disease. The associated factors in our study are mostly contextual factors. Specific and proximal factors 
like lifetime cat exposures or lifetime raw meat consumption were not available from the survey. The same is 
true for the association to lifetime depression, which is only one mood disorder hypothesized to be connected to 
T. gondii infections.
Toxoplasmosis is hard to combat from the public health point of view and often neglected in programs target-
ing food-borne diseases46. Primary prevention of infections is important and can prevent a significant proportion 
of disease cases of all clinical manifestations47. Since a T. gondii infection can reactivate upon immune suppres-
sion, it should be avoided in all population groups to prevent subsequent ocular or cerebral disease later in life.
Secondary prevention in the form of a repeated serological screening during pregnancy might be successful 
to prevent further pregnancy-associated cases. Arguments for serological screening have to consider the positive 
predictive value of the screening tests and the risk-benefit ratio of medication used to treat infection. The effec-
tiveness of prenatal screening and treatment is debated, largely because of different opinions on cost-benefit48,49, 
health consequences of the screening for the mother50, and the effectiveness of the treatment16,51. Nevertheless, 
early serological screening of pregnant women to detect maternal seroconversion, followed by rapid treatment 
in utero (as is done in France and Austria) may prevent transplacental transmission and thus neonatal infec-
tion and clinical manifestation11–14. In these countries, the key for success seems to be frequent re-testing using 
highly sensitive PCR analysis of appropriate maternal samples and rapid treatment2,52. This practice might explain 
the striking differences in percentages of observed hydrocephalus cases in newborns of congenital infections 
seen between France and the US (0.3–0.8% vs. 31%)53–55. In the latter country, this regimen is not practiced. In 
Austria, with its systematic prenatal screening program, a 6-fold decrease in transmission compared to untreated 
women was recently reported56. At the rates of congenital infection reported here, screening is considered to be 
cost-saving57. In Germany, screening tests to detect T. gondii infection during pregnancy are currently not covered 
by statutory health insurance, after scientific evaluation of its pros and cons by their medical services58. As a result, 
pregnant women have to self-pay for these tests. This significantly affects the testing rate, especially in women of 
lower socioeconomic status59.
Patient numbers and preventable cases are expected to be significantly higher than can be inferred from the 
notification system. It should be re-evaluated whether serological testing of pregnant women should be offered 
by physicians and paid for by health insurance in Germany. Moreover, women of childbearing age and those 
immunocompromised should be more specifically targeted and informed about potential risks, with emphasis 
on the prevention of food-borne infection pathways. Finally, veterinary services, the meat industry and agricul-
ture should continue their efforts to reduce T. gondii in meat, especially pork, as this is frequently eaten raw in 
Germany.
Methods
The German health interview and examination survey of adults (DEGS1) was a representative, nationwide 
cross-sectional survey conducted between 2008 and 2011. Detailed study descriptions have been presented pre-
viously26. Briefly, it followed a stratified two-stage cluster sampling strategy to assess the health status of adults 
between 18 and 79 years of age in Germany. Three professionally trained teams each visited a total of 180 sample 
points. The sample points are distributed across Germany according to federal state and municipality size in order 
to reflect the distribution of the German population. After written informed consent 7,988 persons (age 18–79) 
participated in DEGS1. These were interviewed with a standardized questionnaire and blood samples were given. 
The response rate among those approached was 48.4% and the analysis of non-responder questionnaires revealed 
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high population representativeness among participants. Interview data were used to assess potential risk factors 
for positive outcome26. DEGS1 was approved by the ethical review board of the Charité Medical School, Berlin, 
Germany (No. EA2/047/08) and all methods were carried out in accordance with the approved guidelines.
Aliquots of sera (thawed twice) from DEGS1 were analyzed for the presence of anti-T. gondii IgG antibodies 
by a commercial automatic and quantitative enzyme-linked fluorescence assay (ELFA; VIDAS TOXO IgG II; 
Biomérieux SA, France) of the same batch according to the manufacturer’s instructions. In comparative studies, 
sensitivity of the assay was shown to be above 99% and specificity above 98%60. Titers of 0–3 were considered neg-
ative, 4–7 equivocal, and ≥8 positive. We excluded all samples with equivocal test results (1.5%) from the analysis.
Univariable and multivariable logistic regression used sampling weights, accounted for the cluster structure 
of the survey design and checked for effect modifications. Survey weights based on age, sex, residence in West 
or East Germany and nationality (German vs. non-German) were calculated to correct for deviations from the 
German population statistics (December 31, 2010) and used throughout the analysis.
We investigated associations between explanatory variables and seropositivity by univariable logistic regres-
sion analyses. The most frequent category was selected as the reference category except for variables where a 
norm category was available. All variables below p-value of 0.15 were included in a multivariable logistic regres-
sion model. As seropositivity regarding T. gondii is cumulative and therefore strongly related to age, all two-way 
interactions involving age were included. Age-related prevalence was smoothed by using the Lowess procedure of 
the program Stata 12.1 and graphed stratified for sex and East-West geographical origin. The annual incidence of 
seroconversions was calculated from linear regression using the one-year age group as independent and weighted 
prevalence as dependent variable. The annual number of seroconversions among pregnant women between 15 
and 49 years of age in Germany was calculated by using the number of births in each one-year age group of moth-
ers multiplied by the expected proportion of susceptibles, considering an annual incidence of 1,325 in 100,000 
women, and corrected for the mean duration of pregnancies (266 days). For the age group 15 to 17 years, preva-
lence estimates were derived from the study data, assuming a constant increase as in the age group 18 to 25 years.
For the calculation of seroconversions among pregnancies, data on number of women and num-
ber of childbirths by age of the mother for 2011 were retrieved from the German Federal statistical office 
(https://www.destatis.de/). In the calculations we regarded multiple births by looking at how many children each 
respondent had.
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